Reviewer’s report

Title: Inhibition of Airway Remodeling and Inflammatory Response by Icariin in Asthma

Version: 1 Date: 24 Apr 2019

Reviewer: Tetsuhiro Yoshino

Reviewer's report:

This is interesting article which suggesting the usefulness of Icariin for inhibiting the airway smooth muscle proliferation in asthma model mouse. I believe the topic is within the scope of this journal and worth reviewing. This article are well written and structured but authors should address some points listed below.

First of all, I believe a reasoning part for this study should be placed in the introduction section. Authors address the reasoning in the discussion section in current version of their draft; "Years of clinical researches have shown that Epimedium harbor the ability of anti-inflammatory, anti-oxidant and anti-allergic, which are benefit to protect lung tissue and relieve asthma[39-41]." If they could, I hope authors would collect more previous articles about this topic. Otherwise, this topic, Icariin for a treatment of asthma, could sound eccentric for readers.

Additionally, as I read only titles of these references, ref. No.41 sounds irrelevant for current topic.

Next, I hope authors use DXM in figure 1. In current version, hexadecadrol, a synonym of DXM, is used in the figure.

Last, it is very difficult to comprehend the figures. Could you upload figures with high-resolution? I think the label of vertical axis of Figure 2 (C) is Wai/Pbm, possibly.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my
report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors’ responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal